[Myasthenia gravis in children: clinical study of 77 patients]

Shui-zhen Zhou1, Wen-hui Li, Dao-kai Sun

  • 1Department of Neurology, Children's Hospital, Fudan University, Shanghai 200032, China.

Insights

Pediatric myasthenia gravis (MG) shows earlier onset and increased Type II cases. Monitoring serology is crucial as seronegative patients can become positive, and steroids are effective treatments for childhood MG.

Area of Science:

  • Pediatric Neurology
  • Immunology

Background:

  • Myasthenia Gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
  • Understanding pediatric MG clinical characteristics and antibody status is vital for diagnosis and management.

Purpose of the Study:

  • To investigate the clinical features of myasthenia gravis (MG) in children.
  • To analyze changes in acetylcholine receptor antibody (AchR-Ab)-seronegative (SNMG) and seropositive (SPMG) pediatric MG patients.

Main Methods:

  • A retrospective analysis of 77 pediatric MG patients diagnosed between 1992 and 2002.
  • Clinical data, serological markers (AchR-Ab, PremRab, Tintinab), immunological cell counts, imaging (CT), and electromyography (EMG) were assessed.

Main Results:

  • Early onset (before 3 years) was common, with extraocular muscles frequently affected. 35% were initially AchR-Ab positive. Notably, 60% of initially seronegative MG patients (SNMG) converted to seropositive (SPMG) upon follow-up.
  • Abnormalities in CD cells (CD4+, CD3+, CD8+) were observed in 85% of cases. Thymus abnormalities, including hyperplasia and thymoma, were found in 42% and 4% of patients, respectively.
  • Electromyography (EMG) showed abnormalities in 50% of cases. Treatment with anticholinesterase drugs and steroids generally led to good prognosis.

Conclusions:

  • Pediatric MG incidence is rising, with a trend towards younger age of onset and increased Type II classifications.
  • Regular serological monitoring is essential as SNMG patients can seroconvert to SPMG.
  • Corticosteroids, particularly methylprednisolone, are effective and safe for treating pediatric MG, with fewer side effects compared to oral prednisone.
Abstract

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...